Evidence map›Paper›PMID 27104217›Full record

ArticleJACC. Basic to translational science

Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation.

Romain Gallet, Geoffrey de Couto, Eli Simsolo, Jackelyn Valle, Baiming Sun, Weixin Liu, Eleni Tseliou, Michael R Zile, Eduardo Marbán

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Observational
  19. Review
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Romain GalletCedars-Sinai Heart Institute, Los Angeles, CA.
Geoffrey de CoutoCedars-Sinai Heart Institute, Los Angeles, CA.
Eli SimsoloCedars-Sinai Heart Institute, Los Angeles, CA.
Jackelyn ValleCedars-Sinai Heart Institute, Los Angeles, CA.
Baiming SunCedars-Sinai Heart Institute, Los Angeles, CA.
Weixin LiuCedars-Sinai Heart Institute, Los Angeles, CA.
Eleni TseliouCedars-Sinai Heart Institute, Los Angeles, CA.
Michael R ZileMedical University of South Carolina and the RHJ Department of Veterans Affairs Medical Center, Charleston, SC.
Eduardo MarbánCedars-Sinai Heart Institute, Los Angeles, CA.
Ralph H. Johnson VA Medical Center · US

Funding

Electrophysiology and Cell Biology of Cardiac Stem CellsR01HL083109 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI MARBAN, EDUARDO · 2006 to 2014
$3.6M
NHLBI NIH HHS R01 HL083109
6 · The paper itself

Abstract

backgroundThe pathogenesis of HFpEF is unclear, but fibrosis, inflammation and hypertrophy have been put forth as likely contributors. CDCs are heart-derived cell products with anti-fibrotic and anti-inflammatory properties.

objectivesWe questioned whether allogeneic rat CDCs might be able to decrease manifestations of HFpEF in hypertensive rats.

methodsStarting at 7 weeks of age, Dahl salt-sensitive rats were fed a high-salt diet for 6-7 weeks and randomized to receive intracoronary CDCs or placebo. Dahl rats fed normal chow served as controls.

resultsHigh-salt rats developed hypertension, left ventricular (LV) hypertrophy and diastolic dysfunction, without impairment of ejection fraction. Four weeks after treatment, diastolic dysfunction resolved in CDC-treated rats but not in placebo. The improved LV relaxation was associated with lower LV end-diastolic pressure, decreased lung congestion and enhanced survival in CDC-treated rats. Histology and echocardiography revealed no decrease in cardiac hypertrophy after CDC treatment, consistent with the finding of sustained, equally-elevated blood pressure in CDC- and placebo-treated rats. Nevertheless, CDC treatment decreased LV fibrosis and inflammatory infiltrates. Serum inflammatory cytokines were likewise decreased after CDC treatment. Whole-transcriptome analysis revealed major HFpEF-related, CDC-reversed changes in numerous transcripts, including many involved in inflammation and/or fibrosis.

conclusionCDCs normalized LV relaxation and LV diastolic pressure while improving survival in a rat model of HFpEF. The benefits of CDCs occurred despite persistent hypertension and cardiac hypertrophy. By selectively reversing inflammation and fibrosis, CDCs may be beneficial in the treatment of HFpEF.

Indexed as

Animal modelsCell therapydiastolic functionHeart failure with preserved ejection fraction

Identifiers

PMID27104217
PMCPMC4834906
OpenAlexW2310251639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.